PUMA BIOTECHNOLOGY, INC. Cash Flow Statement
PBYI|9 years of annual SEC 10-K data (FY2017-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 9 fiscal years. All figures from audited SEC 10-K filings.
PUMA BIOTECHNOLOGY, INC. generated $27M in operating cash flow and $27M in free cash flow in FY2025. Free cash flow margin was 11.4% of revenue.
Based on SEC 10-K filings.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | $21.6M | $2.0K | -$29.1M | -$60.0M | -$75.6M | -$113.6M | -$292.0M | -$276.0M | -$239.3M |
| Depreciation & Amortization | $11.5M | $9.8M | $11.3M | $10.0M | $8.1M | $7.4M | $2.8M | $1.1M | $776.0K |
| Operating Cash Flow | $27.0M | -$15.8M | $20.6M | $773.0K | $22.4M | -$24.1M | -$172.5M | -$141.7M | -$154.5M |
| Capital Expenditures | $140.0K | $0 | $0 | $46.0K | $306.0K | $170.0K | $170.0K | $4.3M | $1.0M |
| Free Cash Flow | $26.9M | -$15.8M | $20.6M | $727.0K | $22.1M | -$24.3M | -$172.6M | -$146.0M | -$155.5M |
| FCF Margin | 11.4% | -6.9% | 8.2% | 0.3% | 8.1% | -9.7% | -623.6% | -2402.1% | -561.6% |